BGB-3111 CLL: a phase 3 trial of sonrotoclax (BGB-11417) plus zanubrutinib in people with chronic lymphocytic leukaemia

This trial aims to compare sonrotoclax with zanubrutinib compared to venetoclax and obinutuzumab in people with chronic lymphocytic leukaemia (CLL)

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06073821

Trial aim and background

The aim of this trial is to compare the effectiveness of sonrotoclax plus zanubrutinib against venetoclax and obinutuzumab in people with previously untreated CLL.

Venetoclax plus obinutuzumab is the current standard first line treatment for people with CLL. The main purpose of the study is to see whether people who receive sonrotoclax and zanubrutinib live longer without the CLL getting worse compared to those on the standard treatment.

Who can enter 

Adults with untreated CLL requiring treatment may be eligible for this trial.

Locations 

Recruitment is taking place at the following UK locations:

  • University Hospitals Dorset Royal Bournemouth Hospital, Bournemouth
  • Churchill Hospital Oxford University Hospital NHS Trust, Headington
  • Kings College, London
  • Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich
  • East Kent Hospitals University NHS Foundation Trust, Canterbury
  • University College London Hospital, London
  • St James University Hospital, Leeds
  • Royal Marsden Hospital, London
  • Southampton General Hospital, Southampton
  • Manchester Christie, Manchester
  • Dartford and Gravesham NHS Trust, Dartford
  • Clatterbridge Cancer Centre NHS Foundation Trust, Wirral
  • Belfast Health and Social Care Trust, Belfast

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://www.clinicaltrials.gov/study/NCT06073821

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.